038290 On Other Exchanges
Symbol
Exchange
KOSDAQ

macrogen inc (038290) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MACROGEN INC (038290)
\

Related News

No related news articles were found.

macrogen inc (038290) Related Businessweek News

No Related Businessweek News Found

macrogen inc (038290) Details

Macrogen, Inc. provides genome research services in Korea and internationally. The company offers next generation sequencing services, such as whole genome de novo, exome, targeted, transcriptomics, metagenome, and epigenome sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, MLST analysis, sanger sequencing, primer walking, and cloning services. It also provides clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as mRNA, miRNA, SNP, CGH, and DNA methylation; oligo and gene synthesis; and CRISPR design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services. Further, it produces and supplies genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance. The company was founded in 1997 and is based in Seoul, South Korea.

Founded in 1997

macrogen inc (038290) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

macrogen inc
Macrogen and Exosome Plus to Jointly Develop Exosome-Based Diagnostic and Treatment Solutions

Macrogen announced on April 24 that it had signed a supply contract with Exosome Plus on April 19 to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus. The two companies also signed an MOU for the joint development of exosome-based diagnostic and treatment solutions. Under the newly signed contract, Exosome Plus will exclusively supply its high-efficiency exosome isolation kit ‘Exo2DTM’ to Macrogen for one year. Also, according to the contract, Macrogen may sell the isolation kits to third parties. Macrogen will use the isolation kits for its ‘exosomal RNA and DNA sequencing service’ a new high added value product that Macrogen offers to the research market. The use of the isolation kits is expected to improve production efficiency and service stability. Macrogen also plans to sell the isolation kits across its domestic and global distribution network, creating additional profits. In addition to the supply contract, the two companies also signed an MOU for mutual collaboration., Under the MOU, both companies agreed to work together closely for R&D and business development in the areas of exosome-based disease diagnosis and treatment. Specifically, the MOU covers: the development of exosome-based biomarkers for early diagnosis; the development of therapeutic agents; applied uses such as drug delivery carriers, vaccines, and cosmetics; cooperative education and training to foster the manpower necessary for the development of pharmaceuticals; and the joint use of infrastructure, including equipment and facilities.

Macrogen, Inc., Annual General Meeting, Mar 26, 2019

Macrogen, Inc., Annual General Meeting, Mar 26, 2019, at 09:01 Korea Standard Time.

Sistema, RDIF and Macrogen Plan to Jointly Develop Biotechnology in Russia

Sistema PJSFC  and the Russian Direct Investment Fund have agreed with Macrogen to cooperate to develop the biotechnology sector in the Russian Federation following the Eastern Economic Forum. According the trilateral agreement, Sistema, RDIF and Macrogen plan to jointly create conditions for the practical implementation of these developments in Russia and to conduct further research.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

038290 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 038290.
View Industry Companies
 

Industry Analysis

038290

Industry Average

Valuation 038290 Industry Range
Price/Earnings 31.3x
Price/Sales 2.4x
Price/Book 2.2x
Price/Cash Flow 28.4x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MACROGEN INC, please visit www.macrogen.co.kr. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.